The likely drivers are the results release and theReversalof Monday's gain, though no single cause is confirmed in published coverage. Management guided full-year revenue to USD 16.0 million to USD 16.5 million, which implies 154% to 162% growth, and expects most of the USD …
Key HighlightsCoherent (NYSE:COHR) rose 16.79% to USD 225.19 on November 9, 2026, the largest gain in the S&P 500, as optical networking stocks rallied.Monolithic Power Systems gained 16.60% to USD 1,388.05, Astera Labs rose 13.72% and MaxLinear climbed 13.68% in a broad semiconductor rebound.AMD …
Key HighlightsJin Medical International (NASDAQ:ZJYL) indicated USD 3.25 pre-market on November 10, 2026, down 17.7% from a calculated prior close of USD 3.95, after a Monday gain of USD 0.59 or 17.6%.At the Monday close the company had aMarket Valueof USD 30.92 million on …
The raised outlook gave investors confidence that the improvement is durable. Full-year revenue guidance rose to USD 198.2 million to USD 200.7 million from an original range of USD 187.0 million to USD 200.0 million, and adjusted EBITDA guidance rose to USD 32.3 million …
Key HighlightsFlux Power (NASDAQ:FLUX) indicated USD 0.3035 pre-market on November 10, 2026, down 15.9% from a calculated prior close of USD 0.3610, a level that implies aMarket Valuenear USD 6.56 million.Fiscal first-quarterRevenuereported November 3, 2026 was USD 6.758 million, down 48.7% from USD 13.175 …
No catalyst for the decline was identified in published coverage. The most recent company news, around November 9, 2026, was a set of Letters of Intent for commercial collaborations in Malaysia on sovereign border management and security. Earlier, about nine months ago, the company …
The quarter showed operating leverage.Net Incomerose to USD 7.0 million from USD 0.8 million, and adjusted EBITDA more than doubled to USD 11.5 million from USD 5.3 million, even asResearch and Developmentspending rose to USD 11.0 million and selling, general and administrative costs increased …
No catalyst for the move was confirmed in published coverage. Relevant background: on September 16, 2026 the company highlighted the first patient treated in its IDE study of the vCLAS Ultra system for ventricular tachycardia, and about September 23, 2026 it announced a strategic …
No catalyst for Tuesday's decline was identified in published coverage. The company's recent record is relevant: a 1-for-25 reverse split took effect March 23, 2026; fiscal 2025 results came on April 10, 2026; a registered direct offering of up to USD 12.0 million was …
The result gives the company a path into a large market where patients have run out of options, and it validates the drug in a disease where FcRn blockers had not been proven. A randomisedWithdrawaldesign is a demanding test, because it measures whether patients …